IHAN21022 / VX15-2503-12 / KEYNOTE B84 / Baumgart
Research Question:
not to be listed
Basic Study Information
Purpose:
The purpose of the study is to evaluate the safety and tolerability of pepinemab in
combination with pembrolizumab as first-line treatment and determine a recommended
Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous
cell carcinoma (R/M HNSCC).
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Megan Baumgart
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search